Document is current

Article History

Received: 18 January 2023

Accepted: 21 June 2023

First Online: 4 July 2023

Declarations

:

: Not applicable.

: Not applicable.

: SR, TS, and JD declare that they have no competing interests. CC has received cannabinoid capsules in-kind from Tilray Inc. for use in a pilot clinical trial and small grant support from Tilray Inc. to conduct a survey on healthcare practitioner perceptions on barriers impacting cannabis prescribing practices. G. L.’s former employer, the Canadian AIDS Society, has received a grant from Canopy Growth Corporation to support the development of clinical practice guidelines on the use of cannabis and cannabinoid-based medicine for chronic non-cancer pain. Z. W. is an advisory board member of Multidisciplinary Association for Psychedelic Studies — Canada, and for the Canadian Association of Medical Cannabis Dispensaries. He is in the planning phases of becoming an investigator on a survey study sponsored by Doja, from which he does not receive any direct financial compensation; however, graduate students in his lab receive paid research assistantships. He is the coordinating principal investigator on a clinical trial of cannabis for PTSD that is sponsored by Tilray, from which he does not receive any direct financial compensation. Graduate students in his lab receive paid research assistantships from Tilray. SM is the co-owner of a start-up company (“Cannabiscotti Inc.”) that will be applying for a cannabis processing license. She holds shares in Canopy Growth Corporation, Emblem Corp., and Aphria Inc. She has received honorarium for research projects funded by Canopy Growth Corporation and Tilray. A. B. has received funding for consulting, speaking, and/or research from the following commercial organizations: Amgen, Bristol Myers Squibb, Janssen, AstraZeneca, Novartis, Pfizer, Bayer, Lilly, Boehringer Ingelheim, HLS Therapeutics, Spectrum Therapeutics, Sanofi, Bausch Health, Akcea, and Eisai. He has contributed, pro bono, to publications, position statements, and/or clinical practice guidelines from the following noncommercial organizations: Thrombosis Canada, Hypertension Canada, Heart and Stroke Foundation, Canadian Cardiovascular Society, and the Canadian Aids Society. P. J. D. is a consultant for Reformulary Group, a member of the Speakers Bureau for Medical Cannabis Education for Spectrum Therapeutics, and participates in clinical trials for CancerCare Manitoba as per contract requirements. C. M. is the Medical Director of Greenleaf Medical Clinic and Chief Medical Officer for Translational Life Sciences. She is an advisor to PreveCeutical, Pinnacle Care, Africanna, EO Care, Andira Medicine, Active Patch Technologies, Syqe Medical, and Dosist. She was previously on the Board of Directors for The Green Organic Dutchman. Additionally, she has provided medical consultation and/or received support for industry-sponsored continuing medical education from Aleafia, Aurora, Canopy, Tilray, and Emerald Health. E. M. is the co-owner of a start-up company (“Cannabiscotti Inc.”) that will be applying for a cannabis processing license and is employed by MJardin Canada.